{
  "id": "2247619620_1",
  "title": "百济神州、齐鲁、第一三共等纷纷押注，它能否成为实体瘤领域又一「黑马」？",
  "content": "<div class=\"rich_media_content js_underline_content autoTypeSetting24psection\" id=\"js_content\">\n <section data-mpa-action-id=\"maq5wtta153y\" style=\"text-align: center;line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <a class=\"weapp_image_link js_weapp_entry\" data-miniprogram-appid=\"wx33d4c3735820a33e\" data-miniprogram-applink=\"\" data-miniprogram-imageurl=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzghalOStyfXNH59LpTOzBd3AAcZicNFWEvribqS10PiaWLDo6hguOQV7I9Q/640?wx_fmt=png&amp;from=appmsg\" data-miniprogram-nickname=\"Insight医药情报助手\" data-miniprogram-path=\"pages/upgrade/premium/index\" data-miniprogram-servicetype=\"0\" data-miniprogram-type=\"image\" style=\"font-size:15px;\">\n   <img class=\"rich_pages wxw-img\" data-imgfileid=\"100133275\" data-ratio=\"0.26382978723404255\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzghalOStyfXNH59LpTOzBd3AAcZicNFWEvribqS10PiaWLDo6hguOQV7I9Q/640?wx_fmt=png&amp;from=appmsg\" style=\"height: auto !important;\" type=\"block\"/>\n  </a>\n </section>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   提起 Claudin\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （CLDN）\n   </span>\n   家族，大家可能会首先想到已被药企扎堆狂卷的火热靶点\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   CLDN\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   18.2。实际上，在一众药企追捧\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   CLDN\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   18.2 的时候，一些药企已另辟蹊径，瞄上了 CLDN 家族的另一潜力靶点——CLDN6 。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   近期，百济神州在国内启动其 CLDN6×CD3 双抗的临床研究，齐鲁制药也启动了其 CLDN6 ADC 的临床试验。Insight 数据库显示，全球已有十多款 CLDN6 在研管线进入临床，又一个抗肿瘤药物潜力靶点正在悄然出现。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <br/>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;\">\n  <span leaf=\"\">\n   <img alt=\"图片\" class=\"rich_pages wxw-img\" data-backh=\"63\" data-backw=\"562\" data-ratio=\"0.11296296296296296\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZbyM7qmJRCAfwlUl1oKwn1TayYG6lFlSd1iciaYZyh7EJGdZUJpDiat0icIEV7O8Vicibibq7auFa5wDTiaicQ/640?wx_fmt=other&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;random=0.6335062910693781&amp;tp=webp\" style=\"width: 100%;\"/>\n  </span>\n </p>\n <p data-mpa-action-id=\"mboehkdm14pl\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mboehkd1q43\" style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 17px;\">\n  <span leaf=\"\" style=\"\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    CLDN6 ：实体瘤高价值靶点\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   CLDN 是一类紧密连接蛋白，主要在上皮细胞和内皮细胞中表达。目前已发现 27 个 CLDN 家族成员，其中 24 个在哺乳动物中有表达。根据不同 CLDN 的序列同源性水平，这些成员可分为经典 CLDN 和非经典 CLDN 两类。经典 CLDN 成员包括 1-10、14、15、17 和 19，而非经典 CLDN 成员包括 11-13、16、18 和 20-24。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   CLDN 家族成员广泛分布于不同的组织和器官中。研究发现，CLDN 的异常表达与许多肿瘤的发生和发展密切相关，而且其在正常组织和癌症组织中的表达具有明显的差异化，这一特性使它们成为抗肿瘤药物的理想靶点。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   CLDN 家族的明星成员 CLDN 18.2 已率先在实体瘤的药物开发中取得成功。2024 年，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    全球首个 CLDN 18.2 靶向药物佐妥昔单抗\n   </span>\n   <span style=\"color: rgb(136, 136, 136);font-weight: bold;\" textstyle=\"\">\n    （安斯泰来）\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    在日本、欧盟、美国、中国相继获批\n   </span>\n   ，联合化疗用于胃癌或胃食管结合部\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （GEJ）\n   </span>\n   腺癌一线治疗，开辟了 CLDN 家族在癌症治疗中的先河。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   CLDN 18.2 之后，\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   CLDN6 是\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   该家族另一被寄予厚望的潜力靶点。CLDN6 是构成细胞间紧密连接的重要分子，在细胞连接和上皮组织通透性中发挥重要作用。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   CLDN6 和 CLDN18.2 的表达具有明显的不同。例如，在正常组织中，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    CLDN18.2 主要在胃粘膜上皮细胞中表达，而CLDN6 主要在胚胎组织中表达\n   </span>\n   。在癌细胞中，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    CLDN18.2 在胃癌、胃食管结合部腺癌\n   </span>\n   等消化系统肿瘤中高表达，而\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    CLDN6 主要在子宫内膜癌、宫颈癌、卵巢癌、睾丸癌等中表达上调\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   尤为一提的是，与其它 CLDN 家族成员不同，CLDN6 是一种肿瘤特异性蛋白，在健康成人组织中几乎不表达。因此，其被视为实体瘤领域的下一个重要高价值靶点。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <br/>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\">\n   <img alt=\"图片\" class=\"rich_pages wxw-img\" data-backh=\"63\" data-backw=\"562\" data-ratio=\"0.11296296296296296\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZbyM7qmJRCAfwlUl1oKwn1TayYG6lFlSd1iciaYZyh7EJGdZUJpDiat0icIEV7O8Vicibibq7auFa5wDTiaicQ/640?wx_fmt=other&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;random=0.6335062910693781&amp;tp=webp\" style=\"width:100%;\"/>\n  </span>\n </p>\n <p data-mpa-action-id=\"mboeib3i16ow\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mboeib2y22a6\" style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 17px;\">\n  <span leaf=\"\" style=\"\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    全球管线超 30 款，14 款已进入临床\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   根据 Insight 数据库，全球正在开发中的 CLDN6 管线有 33 款\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （仅统计活跃状态，截至 2025/6/6）\n   </span>\n   ， 其中有 14 款已进入临床阶段。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   和 CLDN18.2 管线类似，\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   CLDN6  的\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   药物类型也很多样化，\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   单抗、双抗、三抗、ADC、CAR-T、mRNA 药物、疫苗等，应有尽有。下文将挑选几款已有临床数据公布的代表性药物进行介绍。\n  </span>\n </p>\n <p data-mpa-action-id=\"mbofo4txrdw\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mbofo4to143s\" style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 14px;margin-bottom: 8px;\">\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"\">\n   CLDN6 管线成分类别分布\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-backh=\"293\" data-backw=\"578\" data-imgfileid=\"100135965\" data-ratio=\"0.5061898211829436\" data-s=\"300,640\" data-type=\"png\" data-w=\"727\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8v5zEgibgFwwGzFnU6oCiakd5jqySJjVdXc2AnVpEHxPvl9UezLQDjBuvXKFrvgIJyuHgQKAhOiaBp7A/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;\">\n  <span data-pm-slice=\"0 0 []\" style='color: rgb(178, 178, 178);font-family: mp-quote, -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.408px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;'>\n   <span data-mpa-action-id=\"mal6uvuz24kf\" data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"},\"node\",{\"tagName\":\"span\",\"attributes\":{\"style\":\"color: rgb(178, 178, 178);font-family: mp-quote, -apple-system-font, BlinkMacSystemFont, \\\"Helvetica Neue\\\", \\\"PingFang SC\\\", \\\"Hiragino Sans GB\\\", \\\"Microsoft YaHei UI\\\", \\\"Microsoft YaHei\\\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.408px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;\",\"data-pm-slice\":\"0 0 []\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgba(0, 0, 0, 0.9);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-align: center;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;font-size: 12px;background-color: rgb(255, 255, 255);visibility: visible;'>\n    <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n     截图来源：\n    </span>\n   </span>\n   <span data-mpa-action-id=\"mal6uvuz21z6\" data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgba(0, 0, 0, 0.9);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-align: center;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;font-size: 12px;background-color: rgb(255, 255, 255);visibility: visible;'>\n    <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n     Insight 数据库\n    </span>\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n         <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;letter-spacing: 0.544px;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;visibility: visible;'>\n          <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n          </span>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    新型 CAR-T\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   BioNTech 的 BNT211 是全球进度最快的 CLDN6 CAR-T 疗法，目前正在 Ⅱ 期阶段。值得注意的是，与常规 CAR-T 不同，BNT211 是一款新型的 CAR-T ，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    它的组分中还包括编码 CLDN6 的 CAR-T 细胞扩增的 mRNA 疫苗\n   </span>\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （CARVac）\n   </span>\n   ，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    用以维持 CLDN6 CAR-T 细胞在体内的扩增能力、持久性和有效性\n   </span>\n   。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"243\" data-backw=\"578\" data-imgfileid=\"100135962\" data-ratio=\"0.42021276595744683\" data-s=\"300,640\" data-type=\"png\" data-w=\"1128\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8v5zEgibgFwwGzFnU6oCiakd5jwPia53MZRnpiavZ4FnJzBZoepLTFia1IpVsUXngpOv3WP1qpvjEOTrBg/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p data-mpa-action-id=\"mboeslak1c1u\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mboesl9y78l\" style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 12px;\">\n  <span leaf=\"\" style=\"\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    截图来源：2024 ESMO\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   BioNTech 正在开展两项 BNT211 的临床试验：一项是开放 II 期临床\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （NCT06940804）\n   </span>\n   ，旨在评估 CLDN6 CAR-T 联合或不联合 CARVac 在\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    复发或难治性 Claudin 6 阳性睾丸或性腺外生殖细胞肿瘤\n   </span>\n   男性患者中的抗肿瘤活性和安全性；另一项是Ⅰ/Ⅱ期临床\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （NCT04503278）\n   </span>\n   ，以评估 CLDN6 CAR-T 联合或不联合 CARVac 治疗 CLDN6 阳性复发或难治性晚期实体瘤患者的安全性和初步疗效。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   2024 年 ESMO 大会上公布的 Ⅰ 期临床数据显示，BNT211 ± CARVac 治疗 CLDN6 阳性实体瘤患者整体显示出治疗相关的安全性信号和良好的抗肿瘤活性。截至 2024 年 1 月 8 日，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    59 名患者接受治疗，ORR 为 38%\n   </span>\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    (20/52)\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    ，DCR 为 69%\n   </span>\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    (36/52)\n   </span>\n   ；52 名患者\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （88%）\n   </span>\n   发生了治疗相关不良事件（TRAE），38 例\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （64%）\n   </span>\n   患者出现 3 级以上 TRAE。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-backh=\"483\" data-backw=\"578\" data-imgfileid=\"100135968\" data-ratio=\"0.8354253835425384\" data-s=\"300,640\" data-type=\"png\" data-w=\"717\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8v5zEgibgFwwGzFnU6oCiakd5gAu90yg40ibREdCRFMvMPORMLuqjicGmGUQiclKEqxlTux41WFNS4CK8Q/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;\">\n  <span data-pm-slice='2 2 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' style='color: rgb(178, 178, 178);font-family: mp-quote, -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.408px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;'>\n   <span data-mpa-action-id=\"mal6uvuz24kf\" data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"},\"node\",{\"tagName\":\"span\",\"attributes\":{\"style\":\"color: rgb(178, 178, 178);font-family: mp-quote, -apple-system-font, BlinkMacSystemFont, \\\"Helvetica Neue\\\", \\\"PingFang SC\\\", \\\"Hiragino Sans GB\\\", \\\"Microsoft YaHei UI\\\", \\\"Microsoft YaHei\\\", Arial, sans-serif;font-size: 12px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.408px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;\",\"data-pm-slice\":\"0 0 []\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgba(0, 0, 0, 0.9);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-align: center;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;font-size: 12px;background-color: rgb(255, 255, 255);visibility: visible;'>\n    <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n     截图来源：\n    </span>\n   </span>\n   <span data-mpa-action-id=\"mal6uvuz21z6\" data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgba(0, 0, 0, 0.9);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-align: center;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;font-size: 12px;background-color: rgb(255, 255, 255);visibility: visible;'>\n    <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n     Insight 数据库\n    </span>\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n         <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;letter-spacing: 0.544px;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;visibility: visible;'>\n          <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n          </span>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    体内生成式双抗\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   BioNTech 的 BNT142 是\n   <span style=\"font-weight: normal;\" textstyle=\"\">\n    一种新型的脂质纳米颗粒\n   </span>\n   <span style=\"color: rgb(136, 136, 136);font-weight: normal;\" textstyle=\"\">\n    (LNP)\n   </span>\n   <span style=\"font-weight: normal;\" textstyle=\"\">\n    递送的 mRNA 药物，\n   </span>\n   其是\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    全球首个通过 mRNA 技术实现体内生成双抗的在研药物\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   BNT142  RNA-LNP 静脉注射后会在体内被肝细胞吸收，并翻译成 CLDN6×CD3 双抗 RiboMab02.1 。RiboMab02.1 具有两个 CLDN6 靶向片段和一个 CD3 靶向片段, 可通过同时与 CLDN6 阳性肿瘤和 T 细胞结合，进而诱导肿瘤细胞杀伤。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img js_insertlocalimg\" data-backh=\"281\" data-backw=\"578\" data-imgfileid=\"100135963\" data-ratio=\"0.4864864864864865\" data-s=\"300,640\" data-type=\"png\" data-w=\"962\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8v5zEgibgFwwGzFnU6oCiakd5BE9tbOxyib7iaHCLZqVLOfMxm5UAh53icWrF3jksARjWBERSWjONibreibw/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p data-mpa-action-id=\"mboeslak1c1u\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mboesl9y78l\" style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 12px;\">\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 12px;\",\"mpa-font-style\":\"mboesl9y78l\",\"data-mpa-action-id\":\"mboeslak1c1u\",\"data-pm-slice\":\"0 0 []\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    截图来源：2025 ASCO\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"font-size: 15px;\">\n   BNT142\n  </span>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   正在 CLDN6 阳性晚期实体瘤患者中开展 I/IIa 期\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （NCT05262530）\n   </span>\n   剂量递增及扩展队列试验。2025 年 ASCO 上，BioNTech 公布了该药的首次人体临床试验结果。截至 2024 年 12 月 2 日，65 名患者接受治疗：\n  </span>\n </p>\n <ul class=\"list-paddingleft-1\" style=\"list-style-type: circle;\">\n  <li>\n   <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n    <span leaf=\"\" style=\"font-size: 15px;\">\n     在所有剂量组中 ORR 为 11.5%\n     <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n      （7/61）\n     </span>\n     ，疾病控制率\n     <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n      (DCR)\n     </span>\n     为 57.4%，剂量越高，疗效越显著。\n     <span style=\"font-weight: bold;\" textstyle=\"\">\n      在卵巢癌患者中，有 7 例达到部分缓解\n     </span>\n     <span style=\"color: rgb(136, 136, 136);font-weight: bold;\" textstyle=\"\">\n      (PR)\n     </span>\n     <span style=\"font-weight: bold;\" textstyle=\"\">\n      ，DCR 为 76.2%\n     </span>\n     。\n    </span>\n   </p>\n  </li>\n  <li>\n   <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n    <span leaf=\"\" style=\"font-size: 15px;\">\n     安全性方面，41 名\n     <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n      （63%）\n     </span>\n     患者发生了多为轻度至中度的治疗相关不良事件\n     <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n      (TRAE)\n     </span>\n     ，其中 15 名\n     <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n      （23%）\n     </span>\n     患者出现 ≥3 级 TRAE；2 例\n     <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n      （3%）\n     </span>\n     患者出现剂量限制性毒性。\n    </span>\n   </p>\n  </li>\n </ul>\n <section nodeleaf=\"\" style=\"text-align: center;margin-top: 24px;margin-bottom: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-backh=\"300\" data-backw=\"578\" data-imgfileid=\"100135970\" data-ratio=\"0.5186440677966102\" data-s=\"300,640\" data-type=\"png\" data-w=\"1180\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8v5zEgibgFwwGzFnU6oCiakd576yDUXm77ATg2zQ6CAEUXIQGXu07xCuqiapualkdVs9WBicicLichLibfwQ/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <section>\n  <p data-mpa-action-id=\"mboeslak1c1u\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mboesl9y78l\" style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 12px;\">\n   <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 12px;\",\"mpa-font-style\":\"mboesl9y78l\",\"data-mpa-action-id\":\"mboeslak1c1u\",\"data-pm-slice\":\"0 0 []\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"\">\n    <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n     截图来源：2025 ASCO\n    </span>\n   </span>\n  </p>\n </section>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;margin-top: 24px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   总体来看，BNT142 在较高剂量范围下表现出可控的安全性和初步抗肿瘤活性，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    该研究也为 mRNA 编码的双特异性抗体提供了首个临床概念验证\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;margin-top: 24px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   与传统蛋白双抗相比，mRNA 具有快速生产、剂量灵活等优势。不过，体内 mRNA 持续表达虽然延长了双抗的半衰期，也使 CRS 等不良反应等较难控制，需要有一定的「刹车」机制，以便在毒性发生时可以快速终止抗体生成。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\">\n              <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n              </span>\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n         <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;letter-spacing: 0.544px;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;visibility: visible;'>\n          <span leaf=\"\">\n           <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n           </span>\n          </span>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    ADC\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   TORL-1-23 是 TORL Biotherapeutics 开发的一款靶向 CLDN6 的 ADC，目前正在 Ⅱ 期阶段。\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    该药是 TORL 公司产品管线中进度最快的产品，也是全球进度最快的 CLDN6 ADC\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   2024 年 ESMO 大会上公布的 Ⅰ 期数据显示：每 3 周一次 2.4 mg/kg 和 3.0 mg/kg 剂量给药，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    在 20 例 CLDN6+铂耐药/难治性卵巢癌患者中，9 例\n   </span>\n   <span style=\"color: rgb(136, 136, 136);font-weight: bold;\" textstyle=\"\">\n    (45%)\n   </span>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    获得了深度且持久的确认缓解\n   </span>\n   ，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    两种剂量水平的中位缓解持续时间均超过 6 个月，而且安全性良好\n   </span>\n   。TORL-1-23 治疗 CLDN6 阳性非小细胞肺癌和其它 CLDN6 阳性癌症的 I 期研究评估正在进行中。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-backh=\"324\" data-backw=\"578\" data-imgfileid=\"100135971\" data-ratio=\"0.5610169491525424\" data-s=\"300,640\" data-type=\"png\" data-w=\"1180\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8v5zEgibgFwwGzFnU6oCiakd5oULtqUb7ibDckL7kjicmibUU6Zib50na8nNHDDE73X9ZJladpR8hM7J7zQ/640?wx_fmt=png&amp;from=appmsg\" style=\"width: 100%;\" type=\"block\"/>\n </section>\n <p data-mpa-action-id=\"mboeslak1c1u\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mboesl9y78l\" style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 12px;\">\n  <span data-pm-slice='1 1 [\"para\",null,\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;text-align: center;font-size: 12px;\",\"mpa-font-style\":\"mboesl9y78l\",\"data-mpa-action-id\":\"mboeslak1c1u\",\"data-pm-slice\":\"0 0 []\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style=\"\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    截图来源：2024 ESMO\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   基于 TORL-1-23 在Ⅰ期临床中表现出的卵巢癌治疗积极结果，2024 年 11 月，TORL Biotherapeutics 已启动一项全球 Ⅱ 期临床研究，以评估\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    TORL-1-23 治疗 Claudin 6 阳性晚期铂耐药卵巢癌\n   </span>\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （包括原发性腹膜癌和输卵管癌）\n   </span>\n   女性患者的效果和安全性。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n         <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;letter-spacing: 0.544px;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;visibility: visible;'>\n          <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n          </span>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    治疗性疫苗\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   BNT116 是 BioNTech 开发的\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    一款 RNA-脂质体治疗性癌症疫苗\n   </span>\n   ，由六种 mRNA\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （CLDN6、KK-LC-1、MAGE-A3、MAGE-A4、MAGE-C1 和 PRAME）\n   </span>\n   组成，每种 mRNA 都编码一种在 NSCLC 中经常表达的肿瘤相关抗原\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （TAA）\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   2025 年 AACR 大会上公布的 I 期研究\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （LuCa-MERIT-1）\n   </span>\n   初步数据显示：BNT116 联合西米普利单抗\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    （PD-1）\n   </span>\n   治疗晚期 NSCLC 虚弱患者，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    ORR 为 45%，SD 为 35%，DCR 为 80%，mPFS 为 9.9 个月，整体安全性可控\n   </span>\n   。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <strong data-pm-slice=\"0 0 []\" style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;'>\n   <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);'>\n    <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 200);letter-spacing: 0.544px;\">\n      <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       <strong style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;text-wrap-style: initial;visibility: visible;\">\n        <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgb(0, 180, 204);visibility: visible;\">\n         <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;visibility: visible;\">\n          <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;color: rgb(0, 180, 200);visibility: visible;'>\n           <strong style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;visibility: visible;'>\n            <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(0, 180, 203);visibility: visible;'>\n             <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n             </span>\n            </span>\n           </strong>\n          </strong>\n         </span>\n         <span style='-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;text-indent: 0em;letter-spacing: 0.544px;font-family: -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;visibility: visible;'>\n          <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n           其它产品\n          </span>\n         </span>\n        </span>\n       </strong>\n      </span>\n     </strong>\n    </span>\n   </strong>\n  </strong>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   除了上述药物，还有 10 款 CLDN6 在研管线进入临床阶段，包括 5 款双抗、1 款三抗、3 款 ADC、1 款 CAR-T，这些产品整体都处于Ⅰ期临床阶段。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   其中，第一三共的 DS-9606 是基于其第二个 ADC 平台改良吡咯并苯并二氮杂卓\n   <span style=\"color: rgb(136, 136, 136);\" textstyle=\"\">\n    (PBD)\n   </span>\n   开发的新型 ADC。24 年 ESMO 上公布的数据显示，该药在表达 CLDN6 的晚期实体瘤患者中初步表现了良好的临床活性。其它药物目前尚未披露临床数据。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\">\n   <img class=\"rich_pages wxw-img js_insertlocalimg\" data-imgfileid=\"100135964\" data-ratio=\"0.958974358974359\" data-s=\"300,640\" data-type=\"png\" data-w=\"780\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8v5zEgibgFwwGzFnU6oCiakd5dzR0fdWsAdTjJJqyPO6FO55mY6p20HtNicfezd3zFuc1wP6PjDETLwg/640?wx_fmt=png&amp;from=appmsg\" type=\"block\"/>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\">\n   <br/>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;\">\n  <span leaf=\"\">\n   <img alt=\"图片\" class=\"rich_pages wxw-img\" data-backh=\"63\" data-backw=\"562\" data-ratio=\"0.11296296296296296\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZbyM7qmJRCAfwlUl1oKwn1TayYG6lFlSd1iciaYZyh7EJGdZUJpDiat0icIEV7O8Vicibibq7auFa5wDTiaicQ/640?wx_fmt=other&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;random=0.6335062910693781&amp;tp=webp\" style=\"width: 100%;\"/>\n  </span>\n </p>\n <p data-mpa-action-id=\"mboejp801n8y\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mboejp7d3n2\" style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;font-size: 17px;text-align: center;\">\n  <span leaf=\"\" style=\"\">\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    小结\n   </span>\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   在所有开发 CLDN6 靶向药物的公司中，BioNTech 布局最为全面，进度也是全球领先，其开发了三款 CLDN6 管线，包括 CAR-T、疫苗、体内生成式双抗，这三款产品均已进入临床，并获得初步积极结果，进度在各自赛道均排名第一。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span leaf=\"\" style=\"font-size: 15px;\">\n   国内方面，齐鲁制药、百济神州、泰诚思生物、新石生物、斯丹赛等多家公司也有布局，相关产品都已进入 Ⅰ 期临床阶段，需要等到具体的数据公布后，才能看到真正的效果。\n  </span>\n </p>\n <p style=\"line-height: 1.75em;margin-left: 8px;margin-right: 8px;\">\n  <span data-mpa-action-id=\"mboef84l1icg\" leaf=\"\" style=\"font-size: 15px;\">\n   从目前已公布的早期数据来看，CLDN6 靶向药整体表现出了对多种实体瘤的治疗潜力和良好的安全性。希望随着研究的进行，CLDN6 管线领域可以取得更多的进展和突破，为实体瘤患者带来更多的新型选择。\n  </span>\n </p>\n <section style='-webkit-tap-highlight-color: transparent;margin: 0px 8px 24px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;color: rgba(0, 0, 0, 0.9);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0em;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;background-color: rgb(255, 255, 255);line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 15px;letter-spacing: 0.034em;\">\n  </span>\n </section>\n <section data-role=\"outer\" label=\"Powered by 135editor.com\" style='-webkit-tap-highlight-color: transparent;margin: 0px 0px 0em;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;background-color: rgb(255, 255, 255);color: rgb(34, 34, 34);caret-color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;'>\n  <section data-color=\"#eb6794\" style=\"-webkit-tap-highlight-color: transparent;margin: 1em auto;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.544px;border-width: 0px;border-style: none;border-color: initial;\">\n   <section data-mpa-action-id=\"mbofgm801ro\" data-pm-slice=\"0 0 []\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px auto 0em;padding: 1em;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;height: 10em;line-height: 1.5em;overflow: auto;background-color: rgb(240, 240, 240);\">\n    <section style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;letter-spacing: 0.578px;line-height: 1em;text-align: justify;\">\n     <span data-mpa-action-id=\"mbofgm72d14\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;font-size: 10px;color: rgb(178, 178, 178);letter-spacing: 0.5px;\">\n      <span leaf=\"\" style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n       参考资料：\n      </span>\n     </span>\n    </section>\n    <p style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;letter-spacing: 0.578px;line-height: 1em;text-align: justify;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n     <span data-mpa-action-id=\"mboffpj8jxo\" leaf=\"\" style=\"font-size: 10px;color: rgb(178, 178, 178);letter-spacing: 0.5px;-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n      [1]Claudins in Cancer: A Current and Future Therapeutic Target.https://pmc.ncbi.nlm.nih.gov/articles/PMC11083183/\n     </span>\n    </p>\n    <p style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;letter-spacing: 0.578px;line-height: 1em;text-align: justify;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n     <span leaf=\"\" style=\"font-size: 10px;color: rgb(178, 178, 178);letter-spacing: 0.5px;-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n      [2]The role and mechanism of claudins in cancer.https://pmc.ncbi.nlm.nih.gov/articles/PMC9818346/#abstract1\n     </span>\n    </p>\n    <p style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;letter-spacing: 0.578px;line-height: 1em;text-align: justify;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n     <span leaf=\"\" style=\"font-size: 10px;color: rgb(178, 178, 178);letter-spacing: 0.5px;-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n      [3]Claudin6 (CLDN6): A Emerging Target For Solid Tumor.https://www.biochempeg.com/article/365.html\n     </span>\n    </p>\n    <p style=\"-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;letter-spacing: 0.578px;line-height: 1em;text-align: justify;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n     <span data-mpa-action-id=\"mboffpj81otv\" leaf=\"\" style=\"font-size: 10px;color: rgb(178, 178, 178);letter-spacing: 0.5px;-webkit-tap-highlight-color: transparent;margin: 0px;padding: 0px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;\">\n      [4]Novel Oncology Target Claudin 6 Makes its Case in Solid Tumors.https://www.fiercebiotech.com/sponsored/novel-oncology-target-claudin-6-makes-its-case-solid-tumors\n     </span>\n    </p>\n    <p style=\"text-align: justify;line-height: 1em;\">\n     <span leaf=\"\" style=\"font-size: 10px;\">\n      <span style=\"color: rgb(178, 178, 178);font-weight: normal;\" textstyle=\"\">\n       [5] 各公司官方资料。\n      </span>\n     </span>\n    </p>\n    <p style=\"text-align: justify;line-height: 1em;\">\n     <span data-mpa-action-id=\"mbofgm72w0\" leaf=\"\" style=\"font-size: 10px;\">\n      <span style=\"color: rgb(178, 178, 178);font-weight: normal;\" textstyle=\"\">\n       [6]Insight 数据库\n      </span>\n     </span>\n    </p>\n   </section>\n  </section>\n </section>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;color: rgb(163, 163, 163);\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;visibility: visible;\">\n    <span leaf=\"\">\n     封面来源：站酷海洛\n    </span>\n   </strong>\n   <span style='-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;font-family: -apple-system, system-ui, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;'>\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;text-align: left;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 15px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     免责声明：\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。\n    </span>\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: system-ui, -apple-system, system-ui, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);text-align: left;visibility: visible;line-height: 1.75em;'>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;text-align: left;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;\">\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n     <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;visibility: visible;\">\n      <span leaf=\"\">\n       编辑\n      </span>\n     </strong>\n     <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;\">\n      <span leaf=\"\">\n       ：馨药\n      </span>\n     </span>\n    </span>\n   </strong>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;text-align: left;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;\">\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      PR 稿对接\n     </span>\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb\n    </span>\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;text-align: left;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;\">\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      投稿\n     </span>\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb；邮箱 insight@dxy.cn\n    </span>\n   </span>\n  </span>\n </p>\n <hr style='-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;background-color: rgb(255, 255, 255);caret-color: rgba(0, 0, 0, 0);font-family: system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;border-style: solid;border-right-width: 0px;border-bottom-width: 0px;border-left-width: 0px;border-color: rgba(0, 0, 0, 0.1);transform-origin: 0px 0px;transform: scale(1, 0.5);'/>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.75em;'>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </p>\n <section nodeleaf=\"\" style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: system-ui, -apple-system, system-ui, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);line-height: 1.75em;'>\n  <img alt=\"图片\" class=\"rich_pages wxw-img\" data-backh=\"35\" data-backw=\"542\" data-before-oversubscription-url=\"https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZYnVllCouEEOdqo2iaqqnfQKB92kyKXnTAsX7DloH6icYmFC8LN4mwrwZXeQ5pqqwkDc38ib16FbGZpA/640?wx_fmt=png\" data-copyright=\"0\" data-imgfileid=\"502453994\" data-ratio=\"0.06388888888888888\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZYnVllCouEEOdqo2iaqqnfQKB92kyKXnTAsX7DloH6icYmFC8LN4mwrwZXeQ5pqqwkDc38ib16FbGZpA/640?wx_fmt=other&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp\" style='-webkit-tap-highlight-color: transparent;outline: 0px;text-align: center;text-indent: 0em;color: rgb(48, 48, 48);font-size: 15px;letter-spacing: 1.5px;widows: 1;font-family: \"Helvetica Neue\", Helvetica, \"Hiragino Sans GB\", \"Microsoft YaHei\", Arial, sans-serif;display: initial;visibility: visible !important;width: 1080px !important;height: auto !important;'/>\n </section>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);text-align: center;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;color: rgb(48, 48, 48);font-size: 15px;letter-spacing: 0.544px;\">\n   <span leaf=\"\">\n    多样化功能、可溯源数据……\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);text-align: center;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;color: rgb(48, 48, 48);font-size: 15px;letter-spacing: 0.544px;\">\n   <span leaf=\"\">\n    Insight 数据库网页版等你体验\n    <img alt=\"图片\" class=\"rich_pages wxw-img\" data-imgfileid=\"502453993\" data-ratio=\"1\" data-type=\"png\" data-w=\"64\" src=\"/static/res/logo/https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZapSKkMo4zKejyF1kwocYAdDgiaHuOPBnUFhqWicIL2pJVarklchCnjDxBbdCLIt3FXvuGicJOXnON7A/640?wx_fmt=other&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp\" style=\"-webkit-tap-highlight-color: transparent;outline: 0px;vertical-align: text-bottom;display: inline-block;visibility: visible !important;width: 1080px !important;height: auto !important;\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n    <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\"/>\n   </span>\n  </span>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);font-variant-numeric: normal;font-variant-east-asian: normal;color: rgb(34, 34, 34);font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 16px;background-color: rgb(255, 255, 255);widows: 1;text-align: center;letter-spacing: 1.5px;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;color: rgb(255, 255, 255);background-color: rgb(0, 180, 203);font-size: 15px;\">\n   <span leaf=\"\">\n    点击阅读原文，\n   </span>\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;\">\n    <span leaf=\"\">\n     立刻\n    </span>\n   </strong>\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;\">\n    <span leaf=\"\">\n     解锁\n    </span>\n   </strong>\n   <span leaf=\"\">\n    ！\n   </span>\n  </span>\n  <span leaf=\"\">\n   <img alt=\"图片\" class=\"rich_pages wxw-img\" data-copyright=\"0\" data-imgfileid=\"502453992\" data-ratio=\"0.125\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZsSTG4CvxVOsgyYs36Biav0Peywg39IiboTfliboldm2SDTmYnbfopNhFNPQ8XXlfF9GeoNAGLRM3KQ/640?wx_fmt=other&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp\" style=\"-webkit-tap-highlight-color: transparent;outline: 0px;text-indent: 0em;display: initial;visibility: visible !important;width: 1080px !important;height: auto !important;\"/>\n   <img alt=\"图片\" class=\"rich_pages wxw-img js_darkmode__57\" data-backh=\"120\" data-backw=\"562\" data-copyright=\"0\" data-imgfileid=\"502453995\" data-ratio=\"0.21388888888888888\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZsSTG4CvxVOsgyYs36Biav0IPufv0rfuZIZObNwZ2xqviazG11ia1vlX9hQn3UEf4ExlMrllwicluZ4A/640?wx_fmt=other&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp\" style=\"-webkit-tap-highlight-color: transparent;outline: 0px;text-align: start;color: rgb(51, 51, 51);letter-spacing: 1px;width: 1080px !important;visibility: visible !important;height: auto !important;\"/>\n   <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n   <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n   <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n   <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n   <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\" style=\"height: auto !important;\"/>\n   <img class=\"rich_pages wxw-img\" src=\"/static/res/logo/\"/>\n  </span>\n </p>\n <p style=\"display: none;\">\n  <mp-style-type data-value=\"3\">\n  </mp-style-type>\n </p>\n</div>\n",
  "publish_time": 1749435015,
  "mp_id": "MP_WXS_3975077766",
  "pic_url": "https://mmbiz.qlogo.cn/mmbiz_jpg/lVFg8Ny0F8v5zEgibgFwwGzFnU6oCiakd5JVELwrribiaYKrZnSjibAWMQQ3rEJkoyqVtIx3EwrkldpFYgkFyokErZQ/0?wx_fmt=jpeg",
  "mp_name": "Insight数据库"
}